| 
            Only notified under the "contained use" procedure. Dossier submitted on 24/04/2017.           | 
                  
            A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukaemia           | 
                  
                  
            Humans           | 
                  
            chimeric antigen receptor and suicide-ligand (RQR8)           |